Helicobacter Pylori (H. Pylori) Non-invasive Testing

Helicobacter Pylori (H. Pylori) Non-invasive Testing Market Outlook

The global Helicobacter Pylori (H. Pylori) non-invasive testing market is projected to reach USD 2.1 billion by 2035, with a compound annual growth rate (CAGR) of 6.8% from 2025 to 2035. This growth is driven by the increasing prevalence of H. Pylori infections, which are linked to several gastrointestinal conditions, including peptic ulcers and gastric cancer. Furthermore, the growing awareness of the importance of early diagnosis and treatment for H. Pylori infections propels demand for non-invasive testing methods. Advancements in diagnostic technologies and the rising adoption of point-of-care testing solutions are also significantly contributing to the market's expansion. Additionally, the shift towards preventive healthcare and patient-centric approaches is fostering the development of innovative and accurate diagnostic tools aimed at detecting H. Pylori infection efficiently.

Growth Factor of the Market

Several factors are driving the growth of the H. Pylori non-invasive testing market, with the rise in gastrointestinal diseases being a primary driver. As more people are diagnosed with conditions related to H. Pylori, there is an increasing need for accurate and non-invasive testing methods. Moreover, the technological advancements in diagnostic tools have made it easier and faster to diagnose H. Pylori infections, thus encouraging more healthcare providers to adopt these tests. Furthermore, the increasing focus on patient comfort and the desire to minimize invasive procedures have led to a growing preference for non-invasive testing options. Additionally, the growing awareness among the general population regarding the implications of untreated H. Pylori infections is fostering demand for testing, thus further enhancing market growth. As public health initiatives continue to promote early detection and treatment, the market is expected to witness sustained growth over the forecast period.

Key Highlights of the Market

• The global H. Pylori non-invasive testing market is projected to surpass USD 2.1 billion by 2035.
• A CAGR of 6.8% from 2025 to 2035 reflects the strong demand for accurate diagnostics.
• Technological advancements are pivotal in enhancing the accuracy and efficiency of tests.
• The rise in GERD and other gastrointestinal diseases is a significant market driver.
• Growing patient awareness and preference for non-invasive procedures are reshaping the market landscape.

By Product Type

Urea Breath Test:

The Urea Breath Test (UBT) is one of the most widely used non-invasive tests for detecting H. Pylori infection. During this test, the patient ingests a urea solution labeled with a specific carbon isotope. If H. Pylori is present in the stomach, it will metabolize the urea, producing labeled carbon dioxide that can be detected in the patient's breath. This method is favored for its simplicity, rapid results, and high accuracy. The rising demand for non-invasive diagnostics, combined with its effectiveness in identifying active H. Pylori infections, propels the market segment for UBT. Furthermore, its superior patient compliance compared to invasive methods also contributes to its popularity among healthcare providers.

Stool Antigen Test:

The Stool Antigen Test is another prevalent non-invasive method for detecting H. Pylori infections. This test involves analyzing a stool sample for the presence of specific antigens related to the bacteria. The procedure is straightforward and allows for easy sample collection by patients, making it a preferred option in outpatient settings. The growing emphasis on early detection and treatment of infections is significantly increasing the uptake of stool antigen tests. Additionally, advancements in testing methodologies have enhanced the sensitivity and specificity of this test, leading to improved diagnostic accuracy, thus driving growth in this segment.

Serology Tests:

Serology tests are employed to detect antibodies against H. Pylori in the blood. These tests are useful for diagnosing an active infection and assessing previous exposure to the bacteria. While less commonly used compared to the UBT and stool antigen tests due to their limitations in distinguishing between active and past infections, serology tests remain an essential segment of the market. The increasing demand for comprehensive diagnostic solutions that can provide insights beyond mere presence of the bacterium is driving the development of improved serological assays. Consequently, the serology test segment is positioned to grow as healthcare providers seek more holistic approaches to diagnosing H. Pylori infections.

PCR-based Tests:

PCR-based tests, or polymerase chain reaction tests, represent the most advanced technology for detecting H. Pylori DNA directly from biopsied tissues or stool samples. This method offers unparalleled specificity and sensitivity, making it an invaluable tool for both diagnosis and monitoring of H. Pylori infections. The increasing prevalence of antibiotic-resistant strains of H. Pylori necessitates precise and accurate diagnostic tests, further fueling growth in the PCR-based test segment. As the healthcare industry continues to evolve toward personalized medicine and targeted therapies, the demand for such advanced testing methodologies is expected to rise significantly, enhancing the market's potential.

Others:

This category encompasses various emerging and less commonly used non-invasive testing methods for H. Pylori, including novel diagnostic platforms under development and point-of-care testing technologies. Innovations in molecular diagnostics and advancements in biosensors are paving the way for more convenient and efficient testing solutions. As these technologies mature and gain regulatory approval, they are anticipated to capture a significant share of the H. Pylori testing market. The rapid evolution of diagnostic tools and healthcare trends towards minimal invasiveness are propelling interest in various 'other' testing methods, thus contributing to the overall market growth.

By Application

Hospitals:

Hospitals serve as a primary application area for H. Pylori non-invasive testing due to their capacity to handle large patient volumes and the critical need for accurate diagnostics in acute care settings. The integration of non-invasive testing methods in hospital protocols significantly enhances patient management, as early detection of H. Pylori infections can lead to timely treatment and better outcomes. Hospitals are increasingly investing in advanced diagnostic technologies to improve their service offerings and patient care quality. Moreover, the emphasis on reducing hospitalization times and enhancing patient comfort is driving the demand for non-invasive testing modalities in these institutions.

Clinics:

Clinics, particularly outpatient facilities, are rapidly adopting non-invasive H. Pylori testing to provide patients with accessible and efficient diagnostic services. The convenience of obtaining test results within a short timeframe is attracting more patients to these facilities, thus driving growth in this segment. Moreover, the rising trend of preventive healthcare and regular screenings for gastrointestinal disorders is encouraging clinics to incorporate non-invasive testing into their routine practices. This shift is enhanced by the increasing patient preference for less invasive procedures, making clinics an essential player in the overall market landscape.

Diagnostic Laboratories:

Diagnostic laboratories are crucial in performing H. Pylori testing as they provide a wide range of testing services utilizing advanced technologies. These laboratories cater to healthcare providers by offering reliable and accurate test results, which are essential for effective patient management. The growing number of diagnostic laboratories, along with the increased focus on high-quality testing services, is driving the demand for non-invasive H. Pylori testing. Additionally, the partnerships and collaborations between laboratories and healthcare facilities are expected to enhance the accessibility of testing services, thus contributing to market growth.

Research Institutes:

Research institutes play a pivotal role in advancing the understanding of H. Pylori and developing innovative testing methodologies. Their focus on research and development extends to the exploration of novel non-invasive diagnostic techniques, which can significantly impact the market landscape. As these institutions work on collaborations with industry stakeholders, they contribute to the evolution of testing technologies, thereby enhancing the overall accuracy and efficacy of H. Pylori diagnostics. With increasing funding for gastrointestinal research, especially in relation to H. Pylori, the influence of research institutes on the non-invasive testing market is expected to grow in the coming years.

Others:

This category encompasses various application areas for H. Pylori non-invasive testing, including home healthcare and mobile health services. The rise in telemedicine and home-based healthcare solutions has prompted the development of convenient non-invasive testing kits that can be used by patients in the comfort of their homes. These solutions not only enhance patient compliance but also reduce the burden on healthcare facilities. Additionally, the integration of mobile health technologies and applications is making it easier for patients to manage their health, thus promoting the growth of this segment. As the healthcare landscape continues to evolve, the demand for non-invasive testing across diverse applications is expected to expand significantly.

By Distribution Channel

Hospitals Pharmacies:

Hospital pharmacies are critical distribution channels for H. Pylori non-invasive testing products, as they ensure that tests are accessible to patients who receive treatment within hospital settings. The strategic positioning of testing products in hospitals allows for seamless integration into the patient care process, enabling timely diagnostics and adherence to treatment protocols. With the growing emphasis on patient-centric care, hospital pharmacies are increasingly focused on providing non-invasive testing options that enhance patient comfort and optimize outcomes. This segment is expected to experience significant growth due to the increasing number of procedures and hospital visits related to gastrointestinal disorders.

Retail Pharmacies:

Retail pharmacies are becoming increasingly important as a distribution channel for non-invasive H. Pylori testing products, as they provide patients with greater access to diagnostic services. The convenience of obtaining testing kits directly from pharmacies, along with the availability of counseling from pharmacy staff, enhances patient experience. Moreover, the rise in consumer awareness regarding gastrointestinal health is driving demand for at-home testing solutions available in retail pharmacies. As more patients seek proactive measures to manage their health, retail pharmacies are expected to play a significant role in the distribution of H. Pylori non-invasive testing products, thus aiding market growth.

Online Sales:

The online sales channel for H. Pylori non-invasive testing products is witnessing substantial growth, driven by the increasing trend of e-commerce and the rising comfort level of consumers with online shopping. This channel offers patients the convenience of purchasing testing kits from the comfort of their homes, thus eliminating barriers related to accessibility and travel. Online platforms often provide comprehensive product information and customer reviews, enabling informed decisions. Furthermore, the COVID-19 pandemic has accelerated the shift toward online healthcare solutions, leading to increased demand for at-home testing products. As digital health continues to gain traction, the online sales channel is expected to expand significantly in the coming years.

Others:

This category includes various alternative distribution channels such as telehealth platforms and home healthcare providers. The rise of telemedicine has created opportunities for the distribution of non-invasive testing products through virtual consultations and home delivery services. Patients are able to receive guidance from healthcare professionals on the appropriate tests and have kits sent directly to their homes. Additionally, home healthcare providers are increasingly incorporating non-invasive testing solutions into their service offerings, enhancing patient care and convenience. As healthcare continues to evolve towards more integrated and accessible models, alternative distribution channels are likely to experience significant growth in the H. Pylori non-invasive testing market.

By Technology

Immunoassay:

Immunoassay technology is extensively used in H. Pylori non-invasive testing, particularly in serological and stool antigen tests. This method employs antibody-antigen interactions to detect specific biomarkers related to the H. Pylori infection. Immunoassays are valued for their simplicity, speed, and ability to produce results without the need for complex laboratory equipment. As awareness regarding gastrointestinal health increases, the demand for immunoassay-based testing is anticipated to rise. Furthermore, innovations in immunoassay technologies, including point-of-care testing solutions, are expected to enhance market growth as they improve accessibility and patient outcomes.

Molecular Diagnostics:

Molecular diagnostics, which involve the analysis of nucleic acids, offer high sensitivity and specificity for H. Pylori detection. Techniques such as PCR and next-generation sequencing fall under this category, enabling the accurate identification of the bacterium's genetic material. Molecular diagnostics are increasingly favored in clinical settings due to their ability to detect antibiotic resistance mutations, which is crucial for treatment planning. The growing focus on personalized medicine and targeted therapies is driving the demand for molecular diagnostic methods. Consequently, the segment is expected to experience substantial growth as healthcare providers seek more precise diagnostic tools for managing H. Pylori infections.

Rapid Diagnostics:

The rapid diagnostics segment includes tests that provide quick results, facilitating immediate clinical decision-making. Rapid test kits for H. Pylori detection are designed for ease of use and can deliver results within minutes, allowing for timely treatment initiation. The increasing emphasis on point-of-care testing and the need for fast, reliable diagnostics are driving growth in this segment. Additionally, the rising burden of gastrointestinal diseases necessitates the development of rapid diagnostic solutions that can be deployed in various healthcare settings. As healthcare providers seek to improve efficiency and patient outcomes, the demand for rapid diagnostic tools for H. Pylori is expected to rise.

Others:

This category encompasses emerging technologies and innovative diagnostic solutions that are being explored for H. Pylori detection. These may include biosensors, microfluidics, and lab-on-a-chip technologies, which aim to enhance the convenience and accuracy of H. Pylori testing. Ongoing research and development efforts are focused on creating cost-effective and user-friendly testing solutions that can be easily integrated into routine clinical practice. The global shift toward more advanced and precise diagnostic technologies is expected to drive the growth of this segment, as healthcare providers seek to adopt novel approaches to H. Pylori testing.

By Region

The North American region holds a significant share of the global H. Pylori non-invasive testing market, attributed to the high prevalence of gastrointestinal diseases and advanced healthcare infrastructure. The growing awareness regarding the implications of untreated H. Pylori infections has led to increased demand for effective diagnostic methods. In 2023, North America accounted for approximately 38% of the total market share and is projected to maintain a steady growth rate of around 6.5% CAGR over the forecast period. The presence of key market players and continuous advancements in diagnostic technologies further bolster the market in this region.

In Europe, the H. Pylori non-invasive testing market is also experiencing substantial growth, driven by increasing healthcare expenditure and the rising burden of gastrointestinal disorders. The region accounted for about 30% of the global market share in 2023 and is expected to grow at a CAGR of 7.0% through 2035. The emphasis on improving patient management and the adoption of non-invasive testing methods in clinical settings are significant factors contributing to this growth. As European healthcare systems continue to evolve and adapt to changing patient needs, the demand for H. Pylori non-invasive testing is anticipated to rise.

Opportunities

The H. Pylori non-invasive testing market is poised for significant opportunities driven by technological advancements and increasing investments in research and development. As diagnostic technologies continue to evolve, there is a growing potential for the introduction of innovative testing solutions that enhance accuracy, speed, and patient comfort. Companies that prioritize research and development in this space will have the opportunity to launch next-generation testing platforms that can cater to the specific needs of healthcare providers and patients alike. Additionally, the rising integration of telemedicine and digital health solutions creates avenues for remote testing and monitoring, further expanding market potential.

Furthermore, the growing awareness surrounding gastrointestinal health and the importance of early detection present ample opportunities for market players. Education initiatives aimed at informing patients about the risks associated with H. Pylori infections and the benefits of non-invasive testing can drive demand. Collaborations between healthcare providers, laboratories, and diagnostic companies can also lead to enhanced accessibility of testing solutions in underserved regions. As the healthcare landscape continues to prioritize patient-centric care, the H. Pylori non-invasive testing market is expected to witness significant growth opportunities, ultimately improving patient outcomes and healthcare efficiency.

Threats

Despite the promising growth prospects for the H. Pylori non-invasive testing market, several threats could potentially impede progress. One major concern is the challenge of antibiotic resistance among H. Pylori strains, which complicates treatment regimens and could lead to a decline in test utilization. As resistance rates increase, there may be a growing preference for more comprehensive diagnostic approaches that combine multiple testing modalities, thus impacting the demand for individual non-invasive tests. Moreover, the presence of alternative diagnostic methods and emerging technologies could create competitive pressures, forcing existing players to innovate continuously to maintain their market position.

Additionally, regulatory challenges and the time-consuming process of obtaining approvals for new diagnostic tests can hinder the introduction of innovative solutions in the market. Stringent regulations may slow down the development and commercialization of non-invasive testing products, affecting market dynamics. Furthermore, the economic impact of global events, such as pandemics, could lead to shifts in healthcare priorities and funding, potentially impacting the growth of the H. Pylori non-invasive testing market. Addressing these threats will require proactive strategies from industry stakeholders to ensure sustained growth and innovation in the market.

Competitor Outlook

• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• F. Hoffmann-La Roche AG
• Quest Diagnostics Incorporated
• BD (Becton, Dickinson and Company)
• Siemens Healthineers AG
• Hologic, Inc.
• DiaSorin S.p.A.
• Medline Industries, Inc.
• Bio-Rad Laboratories, Inc.
• Genomic Health, Inc.
• Ortho Clinical Diagnostics
• Everlywell, Inc.
• Chembio Diagnostic Systems, Inc.
• Progenity, Inc.

The competitive landscape of the H. Pylori non-invasive testing market is characterized by a diverse array of players, ranging from established multinational corporations to innovative startups. Major companies such as Thermo Fisher Scientific, Abbott Laboratories, and Roche are leading the charge by offering a comprehensive portfolio of diagnostic solutions and investing heavily in research and development. These companies leverage their extensive networks and distribution channels to ensure the availability of their testing products across various healthcare settings, thereby maintaining a competitive edge. Additionally, their commitment to continuous innovation and technological advancements is evident in the development of new testing methodologies that cater to the evolving needs of healthcare providers and patients.

Moreover, many of these major players are actively engaged in strategic partnerships and collaborations with academic institutions and research organizations to drive innovation and improve diagnostic accuracy. For instance, partnerships with research institutions can facilitate the introduction of novel testing technologies, such as molecular diagnostics and rapid testing solutions, which are becoming increasingly relevant in the current healthcare landscape. Furthermore, the focus on enhancing patient access to testing through telehealth and digital solutions has prompted several companies to explore new distribution channels, such as e-commerce platforms, to reach a broader audience.

In addition to large corporations, smaller companies and startups are emerging as key players in the H. Pylori non-invasive testing market by introducing disruptive technologies and cost-effective solutions. These innovators often focus on niche markets and develop unique testing methodologies that differentiate them from established players. Their agility and adaptability allow them to respond quickly to changing market dynamics and patient needs. As competition intensifies, these emerging players are likely to play a crucial role in shaping the future of the H. Pylori non-invasive testing market, driving innovation, and improving patient outcomes.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Hologic, Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 DiaSorin S.p.A.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Progenity, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Everlywell, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Abbott Laboratories
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Genomic Health, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 F. Hoffmann-La Roche AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Siemens Healthineers AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Medline Industries, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Bio-Rad Laboratories, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Ortho Clinical Diagnostics
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Thermo Fisher Scientific Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Quest Diagnostics Incorporated
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Chembio Diagnostic Systems, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 BD (Becton, Dickinson and Company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Helicobacter Pylori (H. Pylori) Non-invasive Testing Market, By Technology
    • 6.1.1 Immunoassay
    • 6.1.2 Molecular Diagnostics
    • 6.1.3 Rapid Diagnostics
    • 6.1.4 Others
  • 6.2 Helicobacter Pylori (H. Pylori) Non-invasive Testing Market, By Application
    • 6.2.1 Hospitals
    • 6.2.2 Clinics
    • 6.2.3 Diagnostic Laboratories
    • 6.2.4 Research Institutes
    • 6.2.5 Others
  • 6.3 Helicobacter Pylori (H. Pylori) Non-invasive Testing Market, By Product Type
    • 6.3.1 Urea Breath Test
    • 6.3.2 Stool Antigen Test
    • 6.3.3 Serology Tests
    • 6.3.4 PCR-based Tests
    • 6.3.5 Others
  • 6.4 Helicobacter Pylori (H. Pylori) Non-invasive Testing Market, By Distribution Channel
    • 6.4.1 Hospitals Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Sales
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Helicobacter Pylori (H. Pylori) Non-invasive Testing Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Helicobacter Pylori (H. Pylori) Non-invasive Testing market is categorized based on

By Product Type

• Urea Breath Test
• Stool Antigen Test
• Serology Tests
• PCR-based Tests
• Others

By Application

• Hospitals
• Clinics
• Diagnostic Laboratories
• Research Institutes
• Others

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Online Sales
• Others

By Technology

• Immunoassay
• Molecular Diagnostics
• Rapid Diagnostics
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• F. Hoffmann-La Roche AG
• Quest Diagnostics Incorporated
• BD (Becton, Dickinson and Company)
• Siemens Healthineers AG
• Hologic, Inc.
• DiaSorin S.p.A.
• Medline Industries, Inc.
• Bio-Rad Laboratories, Inc.
• Genomic Health, Inc.
• Ortho Clinical Diagnostics
• Everlywell, Inc.
• Chembio Diagnostic Systems, Inc.
• Progenity, Inc.